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Fusions of the human immunodeficiency virus type 1 (HIV-1) transactivator protein Tat to the green fluorescent protein
(GFP) were used to study the intracellular localization, trafficking, and interactions of Tat in human cells. Tagging Tat with GFP
did not change its nuclear localization or ability to act as a transactivator. Tat-GFP expressed at low levels was found in the
nucleus, whereas overexpression resulted in nucleolar accumulation. A Tat-GFP hybrid protein containing in addition the
HIV-1 Rev nuclear export signal (NES) localized predominantly to the cytoplasm. This shuttle protein, Tat-GFP-NES,
transactivated the HIV-1 long terminal repeat. Thus a Tat molecule being only transiently present in the nucleus is active and
nucleolar accumulation of Tat is not prerequisite for function. A coexpression assay previously used to define protein
interaction domains in the HIV-1 Rev protein [R. H. Stauber, E. Afonina, S. Gulnik, J. Erickson, and G. N. Pavlakis (1998a).
Virology 251, 38–48.] indicated that Tat exists predominantly as a monomer and does not form stable multimers with B23 in
living cells. Using a heterokaryon fusion assay, we found that Tat-GFP was able to shuttle between the nucleus and the
cytoplasm. Tat therefore has the potential to perform functions in the nucleus as well as in the cytoplasm.
INTRODUCTION
Transcription of the human immunodeficiency virus
type 1 (HIV-1) is regulated by the virus-encoded Tat
protein and by cellular factors that interact with enhancer
and promoter regions in the HIV-1 long terminal repeat
(LTR) (for detailed reviews see, Peterlin, 1990; Jones and
Peterlin, 1994; Gaynor, 1995; Jones, 1997; Pavlakis, 1997).
Activation of HIV-1 gene expression by Tat is dependent
on a cis-acting RNA stem loop structure, the transacti-
vation response element (TAR), present at the 59 end of
all viral RNAs. Tat is believed to function by interacting
with and directing components of the cellular transcrip-
tion machinery to the vicinity of the HIV-1 promoter (To-
watari et al., 1998) and by stimulating the processivity of
RNA polymerase II (Keen et al., 1996; Mavankal et al.,
1996; Cujec et al., 1997a,b; Mancebo et al., 1997; Wei et
al., 1998). Studies using HIV-1 clones deleted in the tat
gene indicated that Tat appears to be also important for
efficient reverse transcription and hence may function
during preintegration (Harrich et al., 1997). Effects of Tat
have been proposed to affect also uninfected cells. Sev-
eral studies indicated that Tat is released from HIV-
infected cells, endocytosed, and targeted to the nucleus
of uninfected cells, where it can exert a series of pleiotro-
phic effects (Ensoli et al., 1990, 1993; Zauli et al., 1995;
Gibellini et al., 1998). In addition, it was suggested that
Tat enhances also translation efficiencies (Cullen, 1986;
Rosen et al., 1986; Wright et al., 1986) and modulates the
cellular immune response (Viscidi et al., 1989; Seeger et
al., 1997; Conant et al., 1998). The precise mechanisms
by which nuclear Tat can perform these different func-
tions and the role of cellular Tat co-factors are not fully
characterized.
By mutational analysis, two functional domains have
been identified in the 16-kDa two-exon Tat protein. These
include an aminoterminal transcriptional activation do-
main and a highly basic region that is involved in specific
TAR binding and nuclear/nucleolar localization. Tat pro-
teins with mutations in the basic regions display a trans-
dominant (TD) phenotype (Pearson et al., 1990; Modesti
et al., 1991). Since Tat was proposed to dimerize at least
in vitro (Frankel et al., 1988a,b) TD Tat and wild-type Tat
were suspected to form heterodimers inhibiting function
(Pearson et al., 1990).
Protein fusions to the green fluorescent protein
(GFP) are powerful tools not only to study dynamic
processes (for review, see Misteli and Spector, 1997)
but also to probe protein interactions in living cells
(Stauber et al., 1998a). Therefore, we used Tat-GFP
hybrid proteins to address the intracellular localiza-
tion, trafficking, and interactions of Tat. This study also
underlines similarities and differences between the
nuclear/nucleolar viral proteins Rev and Tat and helps
to understand how Tat can perform additional func-
tions besides transactivation.
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RESULTS
Nucleolar accumulation of HIV-1 Tat-GFP is caused
by overexpression
The Tat-GFP fusion protein (Fig. 1) allowed us to study
the localization and trafficking of the HIV-1 Tat protein in
living cells. Tat-GFP contained amino acids 1–86 of the
HIV-1 Tat protein (strain NL4–3) and the complete GFP
protein. Confocal laser scan microscopy (CLSM) of living
HeLa cells, transfected with pTat-GFP, revealed that Tat-
GFP was localized in the nucleus, concentrating at the
nucleolus (Fig. 2A). Expression of untagged Tat by trans-
fection of pTat resulted in similar nucleolar/nuclear lo-
calization as analyzed by indirect immunofluorescence.
Cotransfection of pB37R that is transcribed into an RNA
containing the Tat-binding TAR element did not cause
detectable changes in Tat-GFP localization (data not
shown). The use of a enhanced GFP mutant (Stauber et
al., 1998b) allowed us to study the localization of Tat-GFP
also at low expression levels. In several stable Tat-GFP
HeLa cell lines, we observed a heterogeneous nuclear
Tat-GFP localization (Fig. 2B). In cells stably expressing
higher levels of Tat-GFP, nucleolar accumulation could
still be detected, whereas in low level expressing cells,
Tat-GFP was distributed equally throughout the nucleo-
plasm. The fluorescence signal in the stable cell lines
was on average 25 times lower compared to transient
transfections, and Tat protein concentrations were under
the detection level by indirect immunofluorescence (data
not shown). To verify that the stable Tat-GFP cell lines
express a biologically active protein, the cells were
transfected with the LTR-driven Gag expression plasmid
pB37 together with Rev. As a positive control, the previ-
ously described cell line HLtat, producing untagged Tat
protein, was included. The levels of Tat transactivation in
the stable HeLa Tat-GFP or Tat cell lines, respectively,
were similar, as determined by quantitation of the pro-
duced p24 Gag protein (data not shown). Therefore, the
localization of Tat-GFP observed in the stable cell lines is
not an artifact of a biologically inactive protein, and
nucleolar accumulation of Tat-GFP depends on the ex-
pression level of Tat-GFP.
The HIV-1 Rev nuclear export signal overrides the
nuclear retention of Tat
The localization of a protein within the cell is the net
result of a variety of dynamic processes. To change the
localization of Tat without introducing mutations or dele-
tions, we used a novel strategy by fusing the strong
nuclear export signal (NES) of the HIV-1 Rev protein to
the C terminus of Tat-GFP (Fig. 1). In contrast to the
nuclear/nucleolar localization of Tat-GFP, the steady-
state distribution of Tat-GFP-NES was predominantly cy-
toplasmic, indicating that the NES of Rev was dominant
over the nuclear retention of Tat (Fig. 2C). Similar local-
ization of Tat-GFP-NES was observed in other cell lines
tested (data not shown).
A functional Tat-GFP protein does not have to
accumulate at the nucleolus for transactivation
The localization of Tat in the stable Tat-GFP cell lines
already indicated that nucleolar accumulation was not
prerequisite for Tat function. The predominantly cytoplas-
mic shuttle protein Tat-GFP-NES represented an alterna-
tive approach to test this hypothesis. Thus we compared
the ability of the different Tat-GFP proteins to transacti-
vate HIV-1 LTR directed gene expression. We measured
the expression of HIV-1 gag from the subgenomic ex-
pression vector pB37R, which is dependent on Rev and
Tat activity. HeLa cells were transfected with pB37R and
pBSRev together with different amounts of the Tat ex-
pression plasmids, and Gag production was quantitated
in cytoplasmic extracts (Fig. 3). The presence of either
FIG. 1. Schematic representation of Tat and Tat-GFP expression plasmids. The expression is under the control of the CMV early promoter, and the
constructs contain the bovine growth hormone polyadenylation signal (polyA). pTat encodes the two exon Tat of HIV-1 (NL4–3). pTat-NES expresses
a fusion of Tat with the nuclear export signal (NES) of Rev. pTat-GFP encodes a fusion between Tat and the complete GFP protein. pTat-GFP-NES
expresses a hybrid protein between Tat and a concatemer of two GFP proteins linked by the Rev NES. GFP and NES are not drawn to scale.
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FIG. 2. Localization of Tat-GFP fusion proteins in living human cells. In transiently transfected cells (2 mg of pTat-GFP),Tat-GFP is accumulating at
the nucleolus, whereas Tat-GFP-NES is cytoplasmic (A and C). In stable HeLa cell lines expressing low levels of Tat-GFP, the hybrid protein is
distributed almost equally throughout the nucleus (B).
FIG. 4. The HIV-1 Tat protein exists predominantly as a monomer in living cells. The presence of Tat or Tat-NES did not change the localization
of Tat-GFP-NES or Tat-GFP, respectively. HeLa cells were cotransfected with pTat-GFP-NES (2 mg) and pTat (4 mg) or pTat-GFP (2 mg) together with
pTat-NES (4 mg), respectively, and analyzed by CLSM. The same cells are shown in pictures (A)/(B) or (C)/(D). Tat and Tat-NES were detected by
immunofluorescence using a polyclonal Tat antiserum followed by staining with a rhodamine labeled secondary antibody (B and D). The GFP signal
was used to localize Tat-GFP-NES and Tat-GFP (A and C).
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Tat, Tat-GFP or Tat-GFP-NES, stimulated the expression
of Gag protein ;100-fold. As a control, cotransfection of
pB37R together with pBSRev did not lead to Gag expres-
sion in the absence of Tat (Fig. 3, no Tat). In additional
transfection experiments using as low as 50 ng of plas-
mid DNA, we could not detect significant differences in
transactivation by Tat-GFP and Tat-GFP-NES (data not
shown). Equal transfection efficiencies were ensured by
FIG. 6. Overexpression of the nucleolar protein B23 does not change the localization of Tat-GFP-NES. HeLa cells were cotransfected with
pTat-GFP-NES (2 mg) and pB23 (4 mg) and analyzed by CLSM. The same microscopic field is shown in (A) and (B). B23 was detected by
immunofluorescence (red) using a B23 specific monoclonal antibody followed by staining with a rhodamine conjugated secondary antibody (B). The
GFP signal (green) was used to localize Tat-GFP-NES (A).
FIG. 3. Tat-GFP and Tat-GFP-NES are active in HIV-1 LTR transactivation. HeLa cells were transfected with the indicated amounts of the different
Tat expression vectors, together with 0.2 mg of pBSRev, 2 mg of the gag-expressing plasmid pB37R, and 2 mg of pCMV-GFPsg25. Two days later the
cells were harvested and intracellular Gag production was measured by a p24gag antigen capture assay. Duplicate plates were used and the results
were averaged. Similar results were obtained in two independent experiments. Transfection efficiencies were controlled quantitating GFP as
described.
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adding the plasmid pCMV-GFPsg25 to the transfection
mix and quantitating the GFP signal in cytoplasmic ex-
tracts. The fluorescence resulting from the low amount of
produced Tat-GFP or Tat-GFP-NES protein was not sig-
nificantly higher than the background autofluorescence
and 36-fold lower than the signal emitted by the coex-
pressed GFP (data not shown). This allowed us to use
GFP expression as a transfection control in our assay.
Comparison of the amounts of produced proteins indi-
cated similar expression levels for pTat-GFP and pTat-
GFP-NES. In addition, by Western blot analysis using a
polyclonal Tat antiserum, we could not detect proteolytic
cleavage of Tat-GFP liberating untagged Tat which could
account for the transactivation observed (data not
shown). Therefore, the GFP-tag does not interfere with
Tat’s ability to transactivate, and a Tat molecule that is
only transiently present in the nucleus appears to be
functional in transactivation.
HIV-1 Tat does not form stable multimers in living
cells
The biological activity of Tat-GFP-NES indicated that
the conformation of Tat in the hybrid protein was com-
parable to untagged Tat. Thus we could test if the HIV-1
Tat protein has the potential to form stable multimers in
living cells. Our assay was based on the change of the
distribution of a tagged protein caused by the interaction
with another protein localized in a different subcellular
compartment. We already successfully applied this ap-
proach to define domains important for HIV-1 Rev oligo-
merization (Stauber et al., 1998a). For Rev, cytoplasmic
Rev mutants could be localized to the nucleolus by co-
expression of wild-type Rev, which accumulated at the
nucleolus. We reasoned that if Tat exists predominantly
as a multimer, it should be possible to colocalize the
cytoplasmic shuttle protein Tat-GFP-NES to the nucleo-
lus by Tat–Tat interactions by coexpression of untagged
nucleolar Tat. However, cotransfection of pTat-GFP-
NES even with an excess of pTat, expressing untagged
Tat, did not result in nuclear/nucleolar colocalization of
green Tat-GFP-NES (Fig. 4A). The presence of unlabeled
nuclear/nucleolar Tat in the same cell was verified by a
Tat polyclonal antiserum in combination with a rhoda-
mine-coupled secondary antibody (Fig. 4B). Since GFP
fluorescence was not inactivated by the fixation proce-
dure, it could be used to localize the Tat-GFP-NES fusion
protein. Tat-GFP fluorescence was more sensitive than
antibody staining under these conditions because only
high levels of Tat-GFP-NES were stained in the cyto-
plasm by the Tat antiserum (4B). To control for the pos-
sibility that Tat was relocalized into the cytoplasm by
interaction with Tat-GFP-NES, we cotransfected a two-
fold excess of pTat-NES together with pTat-GFP. pTat-
NES encodes a Tat-NES fusion protein without the GFP-
tag (Fig. 1), and the cytoplasmic localization was visual-
ized by immunofluorescence (Fig. 4D). Figure 4C
illustrates that the nucleolar/nuclear localization of Tat-
GFP was not changed by the presence of the cytoplas-
mic Tat-NES protein in the same cell. We concluded that
Tat does not form stable multimers and, in contrast to
Rev, exists predominantly as a monomer in living human
cells.
The HIV-1 Tat protein can shuttle between the
nucleus and the cytoplasm
Because Tat was suspected to perform additional
functions in the cytoplasm, we investigated if Tat was
capable of nucleo-cytoplasmic trafficking. We used a
standard cell fusion assay in which Tat-GFP-transfected
HeLa cells were fused to untransfected cells using PEG
(Afonina et al., 1998). After PEG treatment the plasma
membranes of the individual cells start to fuse, resulting
in a multinuclear syncytium. If Tat-GFP is constantly
exported from and imported into the donor nucleus, it will
be imported also into the acceptor nuclei present in the
syncytium over time. In Fig. 5A, a single cell expressing
Tat-GFP is surrounded by a layer of nonexpressing cells.
Even long exposure times of the CCD camera did not
reveal detectable amounts of Tat-GFP in the neighboring
cells (data not shown). Figures 5A–5D show the same
microscopic field at various time points after fusion.
Tat-GFP was easily detectable in the closest acceptor
nuclei/nucleoli as early as 30 min postfusion, and after
2 h Tat-GFP was almost equally distributed throughout
the syncytium. De novo protein synthesis was blocked by
cycloheximide in the fusion experiments. Incubation of
Tat-GFP expressing cells at 4°C for as long as 3 h,
shortly after fusion, did not result in trafficking of Tat-GFP
into the surrounding nuclei. Likewise, depleting endog-
enous ATP-pools by treatment with sodium azide and
2-deoxyglusose also blocked Tat-GFP nuclear export. As
a control, a nonshuttling GFP hybrid protein of similar
size (;40 kDa), RevM10BL-GFP, was not exported in our
fusion assay (data not shown). Our results indicate that
the shuttling of Tat is active and not caused unspecifi-
cally by passive diffusion.
Tat does not form stable complexes with B23 in vivo
Marasco et al. (19940 reported that Tat colocalized
with the nucleolar protein B23. Because B23 was re-
ported to be a shuttle protein (Borer et al., 1989), it could
function as a carrier in the nuclear export of Tat. To test
if Tat and B23 form stable complexes, a similar approach
as described to examine Tat–Tat interactions was used.
Figure 6A demonstrates that cotransfection of pTat-GFP-
NES with an excess of pB23, encoding B23, did not
change the cytoplasmic localization of Tat-GFP-NES.
Likewise, immunofluorescence demonstrated high lev-
els of B23 in the nucleolus but not in the cytoplasm in the
presence or absence of the cytoplasmic Tat-GFP-NES
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protein (Fig. 6B). This finding together with the nuclear
but not nucleolar localization of biologically active Tat-
GFP in stable cell lines argues against a stable associ-
ation of Tat and B23 essential for function.
Tat-GFP-NES does not mediate RNA export
Expression of Gag from the subgenomic construct
pB37R, containing the TAR-structure and the Rev RNA
binding site RRE, is dependent on Tat transactivation
and Rev-mediated nucleo-cytoplasmic RNA transport.
If Tat remains stably associated with the TAR structure
during or after transcription, we hypothesized that a
Tat protein that shuttles efficiently should be active in
RNA transport. Since Tat-GFP-NES is a TAR–RNA bind-
ing protein that shuttles via the Rev export pathway,
we tested if it can replace the Rev/RRE axis. Cotrans-
fection experiments of pB37R together with high
amounts of pTat-GFP-NES or Tat-GFP, respectively,
indicated that neither Tat-GFP-NES nor Tat-GFP was
FIG. 5. Nucleo-cytoplasmic trafficking of Tat-GFP in living cells after cell fusion. HeLa cells expressing Tat-GFP were fused by PEG to untransfected
cells, and images were taken at the indicated time points postfusion using a CCD camera. (A) Single cell expressing Tat-GFP surrounded by a layer
of nonproducing cells. (B) The same microscopic field shown 30 min postfusion. Tat-GFP is clearly detectable in the closest acceptor nuclei/nucleoli.
(C) Sixty minutes after fusion. (D) After 2 h Tat-GFP is almost equally distributed throughout the syncytium. To block new protein synthesis,
cycloheximid was present throughout the experiment. Exposure time was slightly increased in (D) to compensate for the decrease of the GFP-signal
caused by the export of Tat-GFP into the acceptor nuclei. Similar export kinetics could be observed in at least three independent experiments.
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able to rescue Gag expression in the absence of Rev
(Fig. 7).
DISCUSSION
The present study demonstrates that fusions of GFP to
the HIV-1 Tat protein result in functional hybrid mole-
cules. In contrast to the HIV-1 Rev-GFP protein, which
was almost completely concentrated at the nucleoli
(Stauber et al., 1995), substantial amounts of Tat-GFP
could be detected in the nucleoplasm. The high propor-
tion of nuclear Tat indicated that the affinity of Tat for the
nucleolus was not as high as Rev’s. This was supported
by the finding that adding the nuclear export signal (NES)
of Rev to Tat resulted in a predominantly cytoplasmic
protein. The steady-state distribution of Tat-NES was
cytoplasmic, suggesting nuclear export being more effi-
cient than nuclear retention. Adding a strong NES to
nuclear proteins represents a novel strategy to influence
protein localization to study the influence of localization
on function. It also underlines that protein localization is
not static but controlled by the fine tuning of signals
mediating nuclear import, export, or nuclear and cyto-
plasmic retention. In stable cell lines expressing low
levels of Tat-GFP, the protein was almost equally distrib-
uted throughout the nucleoplasm. During HIV-1 infection,
the levels of Tat are most likely even lower, suggesting
that nucleolar accumulation is not important for function
but facilitated by overexpression. In addition, transacti-
vation by Tat-GFP-NES demonstrated that a Tat protein
which was only transiently present in the nucleus and
did not accumulate at the nucleolus was able to interact
successfully with the cellular transcription machinery.
Although, we could not detect significant differences in
transcriptional activity comparing low amounts of Tat
versus Tat-NES in transactivation assays it is likely that
nuclear Tat is advantageous, especially at the early
stages of the HIV-1 life cycle. Ongoing experiments will
address the potential of Tat-NES in the context of the
complete virus during infection. Since Tat stimulates the
processivity and not primarily the assembly of the tran-
scription complex (Peterlin, 1990; Jones and Peterlin,
1994; Gaynor, 1995; Jones, 1997) we are currently ad-
dressing if other viral transactivators have to accumulate
in the nucleus for function.
On the analogy of the HIV-1 Rev protein, we found that
Tat was also able to shuttle between the nucleus and the
cytoplasm although, with a three- to fourfold slower
transport rate in our cell fusion assay (R. Stauber, unpub-
lished observations). The transport kinetic of Tat is com-
parable to the shuttling of other trafficking proteins (Dob-
belstein et al., 1997; Roth et al., 1998; Sandri-Goldin,
1998). Therefore Tat represents another nuclear viral
protein that is constantly shuttling between different cel-
lular compartments. Recently, specific signals mediating
nuclear export have been identified (for reviews see
(Go¨rlich and Mattaj, 1996; Nakielny and Dreyfuss, 1997;
FIG. 7. Tat-GFP and Tat-GFP-NES cannot replace Rev function. HeLa cells were transfected with the indicated amounts of the different Tat
expression vectors, together with 2 mg of the gag-expressing plasmid pB37R, 2 mg pCMV-GFPsg25, in the presence or absence of 0.2 mg pBSRev.
Intracellular Gag production was measured by a p24gag antigen capture assay as described. Duplicate plates were used and the results were
averaged. Transfection efficiencies were controlled by quantitating GFP.
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Nigg, 1997)). Analysis of Tat revealed no amino acid
motifs homologous to the known NESs. Testing the N- or
C-terminal half of Tat in a heterologous export system did
not lead to the identification of a linear export signal (R.
Stauber, unpublished observations). However, there are
a variety of fast shuttling proteins like steroid hormone
receptors (Guichon-Mantle et al., 1991; Madan and De-
Franco, 1993) or RNA binding proteins (Lee et al., 1996;
Afonina et al., 1998) where no export signals have been
defined so far. We suggest that the NES of Tat is rela-
tively weak and thus could use an alternative export
pathway than the ‘‘strong’’ leucin-rich NES. Alternatively,
Tat could be transported ‘‘piggy-backed’’ by Tat-interact-
ing proteins. A potential candidate was B23, since it was
reported to shuttle (Borer et al., 1989) and to localize to
the same intranuclear compartment (Marasco et al.,
1994). In our cotransfection assay, Tat and B23 did not
form strong complexes in living cells. The slow trafficking
rate of B23 (.16 h) reported by Borer et al. (1989) argues
also against a predominant role of B23 in Tat’s nucleo-
cytoplasmic transport. Recently, Li (1997) reported inter-
action between B23 and Tat and cytoplasmic relocaliza-
tion of Tat by cotransfection with a hybrid protein be-
tween b-galactosidase (bgal) and a part of B23.
However, it has to be clarified if the relocalization of Tat
was specific or was caused by the disturbance of the
nucleolar structure by overexpression of the bgal-B23
hybrid protein which would result in cytoplasmic accu-
mulation of Tat due to its shuttling activity. In addition, we
observed that in stable cell lines Tat-GFP being not
concentrated at the nucleolus was yet functional. We
reasoned that the nucleolus, especially 5S-RNA, as sug-
gested for Tat and Rev (Giel-Pietraszuk et al., 1997; Lam
et al., 1998), or B23 may represent secondary binding
sites for Tat when other primary nuclear binding sites are
saturated.
Demonstrating that Tat is not confined to the nucleus
helps to understand how Tat can perform additional
functions besides transcriptional activation in the cyto-
plasm. Among those, it was suggested that Tat enhances
translation efficiency (Cullen, 1986; Rosen et al., 1986;
Wright et al., 1986; Hauber et al., 1987; Braddock et al.,
1993) and is necessary for efficient reverse transcription
(Huang et al., 1994; Harrich et al., 1997). The latter could
be mediated by incorporation of cytoplasmic Tat into the
virion. In addition, it was demonstrated that Tat is effi-
ciently released from HIV-1 infected cells (Ensoli et al.,
1993; Zauli et al., 1995; Gibellini et al., 1998). Thus the
shuttling of Tat would provide a continuous source to
maintain extracellular secretion.
To stimulate transcription, Tat has to bind to the TAR
structure and subsequently to interact with factors stim-
ulating the processivity of the RNA polymerase II holoen-
zyme (RNAPolII) (Jones, 1997). An indirect approach to
test whether Tat remains tightly associated with TAR was
to assay if Tat could function in RNA export via Tat/TAR
interaction. In analogy to the bacteriophage MS2 system
(Venkatesan et al., 1992), the Tat/TAR interaction should
also be able to replace the Rev/RRE axis (reviewed in
Felber, 1997). Adding the efficient Rev NES to Tat-GFP
ensured that the shuttling protein Tat-GFP-NES was tar-
geted to the appropriate Rev export pathway. However,
the interaction of Tat-GFP-NES with TAR could not sub-
stitute for Rev/RRE interaction. This is in agreement with
data from experiments using the HIV-1 Tev protein. Tev
which contains TAR-binding activity (by the Tat portion)
and shuttling activity (mediated by the Rev portion) was
also unable to substitute for Rev (D’Agostino, unpub-
lished observations). These findings suggest that Tat is
not bound efficiently to the TAR structure during or after
transcription. Alternatively, since Tat exists predomi-
nantly as a monomer, multimerization might be prereq-
uisite to mediate RNA export as demonstrated for Rev
(Stauber et al., 1998a; Thomas et al., 1998). Recently,
Keen et al. (1997) demonstrated that the TAR–RNA does
not remain associated with the Tat-RNAPII complex and
a high-affinity TatTAR complex exists only transiently
during the initial phase of transcription (Wei et al., 1998).
To achieve RNA export by a Tat-Rev hybrid protein, Luo
et al. (1993) had to use an array of 12 TAR elements. This
set-up ensured that even after transcription sufficient
Tat-Rev hybrid molecules remained attached to the mul-
tiple TAR elements to mediate RNA export.
Reports on Tat as a metal-linked dimer were based on
studies using prokaryotic produced Tat protein (Frankel
et al., 1988a,b). However, Waszak et al. (1992) were able
to purify an active monomeric recombinant Tat protein
from Escherichia coli. We observed that cotransfection of
Tat with Tat-GFP-NES or Tat-GFP together with Tat-NES,
respectively, did not change the localization of the
tagged Tat proteins. This provided evidence that Tat
exists predominantly as a monomer in living human
cells. In contrast to Tat, cytoplasmic localized Rev mu-
tants could be colocalized to the nucleolus upon coex-
pression of wild-type Rev, demonstrating the feasibility of
this in vivo approach (Stauber et al., 1998a). However, we
can not completely exclude the possibility that Tat exists
transiently as a loose oligomer. The data from Rice and
Chan (1991) who showed that Tat is a monomer in cell
extracts are also in agreement with our finding. Demon-
strating that Tat is predominantly a monomer in vivo
favors the model that trans-dominant (TD) Tat mutants
inhibit the activity of wild-type Tat by sequestering cellu-
lar cofactors (Modesti et al., 1991; Carroll et al., 1992)
rather than by the formation of inactive heterocomplexes
as suggested for TD Rev (Hope et al., 1992; Stauber et al.,
1995, 1998a; Szilvay et al., 1995). Visualizing the nucleo-
cytoplasmic shuttling of Tat explains how even cytoplas-
mic Tat mutants can be TD (Orsini and Debouck, 1996).
In summary, we have demonstrated that fusions to
GFP can be used to study the structure, function, and
interactions of the HIV-1 Tat protein. Our results suggest
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that Tat exits predominantly as a monomer and nucleolar
accumulation of Tat is not necessary for transactivation.
A Tat molecule being present only transiently in the
nucleus appears to be sufficient to stimulate the proces-
sivity of the RNA-PolII machinery. Tat is able to shuttle
between the nucleus and cytoplasm, suggesting that Tat
has the potential to perform additional functions in the
cytoplasm which makes it again an attractive target for
antiviral approaches.
MATERIALS AND METHODS
Cells and transfections
The human cell lines HeLa and 293 (Stauber et al.,
1995) were used for microscopic studies and to measure
LTR directed transactivation by Tat. HLtat is a HeLa-
derived cell line that constitutively produces Tat protein
(Schwartz et al., 1990). Cells were transfected by the
calcium phosphate coprecipitation technique, and cyto-
plasmic extracts were prepared as described (Stauber et
al., 1995). The production of intracellular HIV-1 Gag pro-
tein was measured by a p24gag antigen capture assay
(Cellular Products) as described (Stauber et al., 1995). To
control for transfection efficiencies, 2 mg of the GFP-
expressing plasmid pCMV-GFPsg25 (Stauber et al.,
1998b) was cotransfected with the indicated plasmids.
The GFP signal in cytoplasmic extracts was quantitated
in a Cytofluor II plate reader (Perseptive Biosystems, MA)
as described (Stauber et al., 1998b).
Recombinant plasmids
pBsrev produces HIV-1 Rev from the HIV-1 LTR pro-
moter (D’Agostino et al., 1995). Plasmid pB37R contains
the HIV-1 59 LTR promoter, the p37gag coding region,
RRE330, and the HIV-1 39 LTR (Stauber et al., 1995). This
construct expresses gag in a Tat- and Rev-dependent
manner. Plasmid pCMV-GFPsg25 encodes a mutated
GFP protein under the control of the early CMV promoter
(Stauber et al., 1998b). To generate pTat-GFP, the coding
region of the HIV-1 two exon Tat (strain NL4–3) was
amplified by PCR using appropriate primers containing
NheI restriction sites. The PCR product was digested
with NheI and cloned into the NheI cut vector pCMV-
GFPsg25. In the construct pTat, the GFP open reading
frame (ORF) was removed by digesting pTat-GFP with
EcoRV and HpaI. To generate a Tat protein containing the
Rev nuclear export signal (NES), complementary oligo-
nucleotides coding for the Rev NES (amino acids PLQLP-
PLQRLTLN), were annealed and cloned into the EcoRV/
HpaI-digested pTat-GFP after removal of the DNA frag-
ment encoding GFP. The resulting construct pTat-NES
produces a Tat protein fused to the HIV-1 Rev NES.
pTat-GFP-NES expresses a Tat-GFP hybrid protein con-
taining the Rev NES. To obtain this plasmid, the GFP ORF
of pCMV-GFPsg50 (Stauber et al., 1998b) was PCR am-
plified and cloned into the NheI site of pCMV-GFPsg25.
This resulted in the plasmid pCMV-GFP50–25, which
codes for a fusion of two GFP proteins connected by a
linker sequence. This linker contained AflII and KpnI
restriction sites in which the Rev NES was cloned using
appropriate complementary oligonucleotides. The result-
ing construct pCMV-GFP50-RevNES-25 was digested
with PmlI, and the DNA fragment containing the Rev NES
was cloned into the PmlI-digested plasmid pTat-GFP.
Plasmid pB23 encodes the nucleolar protein B23 under
the control of the early CMV promoter and was con-
structed by digesting pF25-B23-GFP with EcoRV/HpaI,
thereby removing the DNA fragment containing the GFP
ORF. The plasmid pBsrevM10BL-GFP, coding for a HIV-1
Rev protein lacking the NES, was described earlier
(Stauber et al., 1995). All plasmids were verified by se-
quence analysis as described (Stauber et al., 1995).
Cell fusion assay
HeLa cells transfected with pTat-GFP were seeded
24 h posttransfection with a fivefold excess of untrans-
fected HeLa cells. The following day, cells were washed
with PBS, and 2 ml of PEG (PEG-4000, 50% in PBS)
(GIBCO BRL) was added for 2 min. Cells were exten-
sively washed with PBS and further incubated at 37°C.
All solutions were prewarmed to 37°C prior to use. To
block new protein synthesis cycloheximide (25 mg/ml)
was added 30 min before fusion and was present during
the experiment. Cells were observed under phase con-
trast and fluorescent illumination and scanned for fusion
involving one GFP-Tat donor cell and nonexpressing sur-
rounding acceptor cells. For energy depletion, sodium
azid (10 mM) and 2-deoxxglucose (6 mM) (Sigma) in
glucose-free DMEM were added to the cells 30 min prior
to fusion and were present during the experiment.
Microscopy
Cells were seeded into coated 50-mm glass-bottom
dishes (MatTek Corp., Ashland, MA) in phenol-red-free
DMEM and transfected 24 h later with the indicated
plasmids. One day later, the cells were analyzed by a
Zeiss LSM 410 Micro System in the confocal mode. For
GFP excitation, an argon/krypton laser at 488-nm wave-
length was used and emitted fluorescence was detected
with a 515- to 540-nm band-pass filter. For rhodamine red
excitation, a 568-nm helium/neon laser was used, and
fluorescence was detected with a 590-nm cut-off filter.
Normaski images were made using a 543-nm green
laser and appropriate polarized lenses.
Alternatively, cells were observed with an inverted
fluorescence microscope (Zeiss Axiovert 135). GFP sig-
nals were obtained with a FITC-fluorescence filter set
(Zeiss O9, excitation 450–490 nm, beam splitter 510 nm,
emission filter .520 nm). Twelve-bit black-and-white im-
ages were captured using a digital CCD camera (Pho-
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tometrix, AZ). Image analysis and presentation were per-
formed using the IPLab Spectrum software (Scanalytics,
Vienna, VA). The nuclear signal was obtained by mea-
suring the pixel intensity in the nucleus. All pixel values
were measured below saturation limits.
Generation of stable Tat-GFP expressing cell lines
HeLa cells were transfected with the plasmid pTat-
GFP by the calcium phosphate method. Two days after
transfection single cell FACS sorting was performed into
96-well plates as described (Stauber et al., 1998b). Pos-
itive, Tat-GFP-expressing, single-cell clones were identi-
fied using an inverted fluorescence microscope and fur-
ther expanded in G418-containing DMEM (500 mg/ml).
Indirect immunofluorescence
Transfected cells were fixed and permeabilized as
described (Stauber et al., 1995). The cells were incu-
bated with a polyclonal rabbit anti-Tat antiserum (Felber
et al., 1990) (diluted 1:100 in PBS) or a monoclonal mouse
anti-B23 antibody (undiluted hybridoma supernatant) for
1 h. Appropriate secondary rhodamine conjugated anti-
IgG antibodies (KRL) (diluted 1:200 in PBS) were added
for 1 h, and cells were analyzed by microscopy. Extensive
washings with PBS were performed after each step
throughout the procedure.
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